Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:DPY19L4-ALG5

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: DPY19L4-ALG5
	FusionPDB ID: 24086
	FusionGDB2.0 ID: 24086
		Hgene	Tgene
	Gene symbol	DPY19L4	ALG5
	Gene ID	286148	29880
	Gene name	dpy-19 like 4	ALG5 dolichyl-phosphate beta-glucosyltransferase
	Synonyms	-	bA421P11.2
	Cytomap	8q22.1	13q13.3
	Type of gene	protein-coding	protein-coding
	Description	probable C-mannosyltransferase DPY19L4dpy-19-like protein 4protein dpy-19 homolog 4	dolichyl-phosphate beta-glucosyltransferaseAlg5, S. cerevisiae, homolog ofasparagine-linked glycosylation 5 homolog (S. cerevisiae, dolichyl-phosphate beta-glucosyltransferase)asparagine-linked glycosylation 5 homolog (yeast, dolichyl-phosphate beta-gl
	Modification date	20200313	20200313
	UniProtAcc	Q7Z388 Main function of 5'-partner protein: FUNCTION: Probable C-mannosyltransferase that mediates C-mannosylation of tryptophan residues on target proteins. {ECO:0000250}.	Q9Y673 Main function of 5'-partner protein:
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000414645,	ENST00000413537, ENST00000496689, ENST00000239891, ENST00000443765,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	4 X 3 X 4=48	6 X 5 X 5=150
	# samples	5	6
	** MAII score	log2(5/48*10)=0.0588936890535686 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0	log2(6/150*10)=-1.32192809488736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: DPY19L4 [Title/Abstract] AND ALG5 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: DPY19L4 [Title/Abstract] AND ALG5 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	DPY19L4(95782799)-ALG5(37526736), # samples:1
Anticipated loss of major functional domain due to fusion event.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:95782799/chr13:37526736)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across DPY19L4 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ALG5 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000414645

DPY19L4

chr8

95782799

ENST00000443765

ALG5

chr13

37526736

1922

1553

1754

551

ENST00000414645

DPY19L4

chr8

95782799

ENST00000239891

ALG5

chr13

37526736

1867

1553

1754

551

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000414645	ENST00000443765	DPY19L4	chr8	95782799	+	ALG5	chr13	37526736	-	0.000468028	0.999532
ENST00000414645	ENST00000239891	DPY19L4	chr8	95782799	+	ALG5	chr13	37526736	-	0.00055923	0.9994407

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for DPY19L4-ALG5

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
DPY19L4	chr8	95782799	ALG5	chr13	37526736	1553	485	TILLGSLAMVIEGAFDVELLYIAQFF

Top

Potential FusionNeoAntigen Information of DPY19L4-ALG5 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

DPY19L4-ALG5_95782799_37526736.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:25	GAFDVELLY	0.999	0.9585	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:02	GAFDVELLY	0.997	0.9655	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:08	GAFDVELLY	0.9963	0.9082	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:17	GAFDVELLY	0.9958	0.9391	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:01	GAFDVELLY	0.9938	0.9401	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:01	LAMVIEGAF	0.9851	0.918	6	15
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A02:22	SLAMVIEGA	0.9831	0.6823	5	14
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:01	GAFDVELLY	0.9802	0.8923	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A02:35	MVIEGAFDV	0.976	0.6723	8	17
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A02:21	MVIEGAFDV	0.976	0.7286	8	17
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A02:38	SLAMVIEGA	0.9756	0.7537	5	14
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:05	LAMVIEGAF	0.9749	0.5753	6	15
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A02:20	MVIEGAFDV	0.9732	0.6317	8	17
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A02:11	MVIEGAFDV	0.9632	0.6578	8	17
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B58:01	GAFDVELLY	0.9524	0.9273	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:16	GAFDVELLY	0.9393	0.8035	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:05	GAFDVELLY	0.8859	0.7016	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:03	GAFDVELLY	0.8365	0.8299	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B58:02	GAFDVELLY	0.7845	0.9334	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B47:01	GAFDVELLY	0.5177	0.5656	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B39:13	IEGAFDVEL	0.3942	0.8791	10	19
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A32:13	GAFDVELLY	0.2277	0.9116	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:01	EGAFDVELLY	0.9343	0.8787	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B44:03	IEGAFDVELLY	0.9886	0.9353	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B18:01	IEGAFDVELLY	0.9488	0.9497	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:05	GAFDVELLY	0.9973	0.9369	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:21	GAFDVELLY	0.9969	0.9446	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:31	GAFDVELLY	0.9939	0.9418	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A02:05	MVIEGAFDV	0.9676	0.6174	8	17
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:07	GAFDVELLY	0.9511	0.7466	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C15:04	GAFDVELLY	0.9388	0.938	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C07:19	GAFDVELLY	0.8808	0.7594	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C07:95	GAFDVELLY	0.862	0.735	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C07:27	GAFDVELLY	0.7879	0.9673	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:04	GAFDVELLY	0.6042	0.9199	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B39:08	IEGAFDVEL	0.563	0.7092	10	19
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C03:14	GAFDVELLY	0.4318	0.9866	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C06:03	GAFDVELLY	0.3338	0.9935	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C12:04	GAFDVELLY	0.3283	0.9925	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C12:12	GAFDVELLY	0.2894	0.9283	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:31	EGAFDVELLY	0.9326	0.8501	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:39	GAFDVELLY	0.9989	0.887	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B40:04	IEGAFDVEL	0.9977	0.6909	10	19
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:20	GAFDVELLY	0.9975	0.9626	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:11	GAFDVELLY	0.9966	0.938	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:28	GAFDVELLY	0.9959	0.9618	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A68:02	MVIEGAFDV	0.9949	0.9253	8	17
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:77	GAFDVELLY	0.9938	0.9401	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:23	GAFDVELLY	0.9936	0.9305	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:20	GAFDVELLY	0.9936	0.9657	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A69:01	MVIEGAFDV	0.9925	0.8704	8	17
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:11	LAMVIEGAF	0.9905	0.947	6	15
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C03:02	LAMVIEGAF	0.9901	0.9726	6	15
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B57:04	GAFDVELLY	0.9869	0.7668	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A02:03	SLAMVIEGA	0.9864	0.7902	5	14
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:77	LAMVIEGAF	0.9851	0.918	6	15
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:23	LAMVIEGAF	0.985	0.9297	6	15
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:27	GAFDVELLY	0.9813	0.8856	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:33	GAFDVELLY	0.9802	0.8923	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:125	GAFDVELLY	0.9802	0.8923	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:34	GAFDVELLY	0.9802	0.8923	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:135	GAFDVELLY	0.9796	0.8973	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:17	GAFDVELLY	0.9771	0.87	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:30	GAFDVELLY	0.9771	0.87	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A02:14	MVIEGAFDV	0.977	0.6581	8	17
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:50	GAFDVELLY	0.9766	0.9373	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:17	LAMVIEGAF	0.9761	0.8057	6	15
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:30	LAMVIEGAF	0.9761	0.8057	6	15
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A02:06	MVIEGAFDV	0.976	0.7286	8	17
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:13	GAFDVELLY	0.9743	0.7133	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:11	GAFDVELLY	0.9732	0.833	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:43	LAMVIEGAF	0.9715	0.8827	6	15
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:08	GAFDVELLY	0.9645	0.8429	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C03:02	GAFDVELLY	0.9625	0.9759	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:24	LAMVIEGAF	0.9592	0.9168	6	15
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:43	GAFDVELLY	0.9547	0.8487	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:24	GAFDVELLY	0.9407	0.8652	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C15:09	GAFDVELLY	0.9388	0.938	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:35	GAFDVELLY	0.9322	0.8939	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:12	GAFDVELLY	0.9315	0.9028	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:24	GAFDVELLY	0.9153	0.9494	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C07:22	GAFDVELLY	0.8937	0.7135	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C07:01	GAFDVELLY	0.8587	0.684	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:53	GAFDVELLY	0.854	0.8455	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B58:06	GAFDVELLY	0.8249	0.8772	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B48:02	GAFDVELLY	0.821	0.9598	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C07:17	GAFDVELLY	0.8023	0.9724	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C12:02	GAFDVELLY	0.6116	0.9682	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C16:04	GAFDVELLY	0.594	0.9856	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:54	GAFDVELLY	0.5534	0.8267	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B18:04	GAFDVELLY	0.4485	0.9623	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B39:02	IEGAFDVEL	0.432	0.8952	10	19
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C12:03	GAFDVELLY	0.3709	0.9772	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C16:02	GAFDVELLY	0.3694	0.9926	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B41:03	IEGAFDVEL	0.3488	0.5077	10	19
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C16:01	GAFDVELLY	0.3229	0.9799	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B18:07	GAFDVELLY	0.2102	0.9238	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C02:02	GAFDVELLY	0.0567	0.9795	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-C02:10	GAFDVELLY	0.0567	0.9795	12	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:77	EGAFDVELLY	0.9343	0.8787	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:23	EGAFDVELLY	0.9319	0.8424	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:20	EGAFDVELLY	0.9061	0.9247	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:11	EGAFDVELLY	0.8774	0.7917	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B15:08	EGAFDVELLY	0.8714	0.8075	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:24	EGAFDVELLY	0.8505	0.9127	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:43	EGAFDVELLY	0.8493	0.8127	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:17	EGAFDVELLY	0.7488	0.6612	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:30	EGAFDVELLY	0.7488	0.6612	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A25:01	EGAFDVELLY	0.6322	0.7921	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B18:04	EGAFDVELLY	0.6275	0.9405	11	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-A02:14	MVIEGAFDVEL	0.9915	0.6424	8	19
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B44:13	IEGAFDVELLY	0.9886	0.9353	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B44:07	IEGAFDVELLY	0.9886	0.9353	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B44:26	IEGAFDVELLY	0.9886	0.9353	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:28	IEGAFDVELLY	0.9831	0.9303	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B18:11	IEGAFDVELLY	0.9801	0.8826	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B35:20	IEGAFDVELLY	0.9792	0.9352	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B18:04	IEGAFDVELLY	0.9603	0.9574	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B18:06	IEGAFDVELLY	0.955	0.9524	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B18:08	IEGAFDVELLY	0.9509	0.8901	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B18:05	IEGAFDVELLY	0.9488	0.9497	10	21
DPY19L4-ALG5	chr8	95782799	chr13	37526736	1553	HLA-B48:02	IEGAFDVELLY	0.9206	0.9203	10	21

Top

Potential FusionNeoAntigen Information of DPY19L4-ALG5 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of DPY19L4-ALG5

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
4768	LAMVIEGAFDVELL	DPY19L4	ALG5	chr8	95782799	chr13	37526736	1553

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of DPY19L4-ALG5

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	4768	LAMVIEGAFDVELL	-7.15543	-7.26883
HLA-B14:02	3BVN	4768	LAMVIEGAFDVELL	-4.77435	-5.80965
HLA-B52:01	3W39	4768	LAMVIEGAFDVELL	-6.80875	-6.92215
HLA-B52:01	3W39	4768	LAMVIEGAFDVELL	-4.20386	-5.23916
HLA-A11:01	4UQ2	4768	LAMVIEGAFDVELL	-7.5194	-8.5547
HLA-A11:01	4UQ2	4768	LAMVIEGAFDVELL	-6.9601	-7.0735
HLA-A24:02	5HGA	4768	LAMVIEGAFDVELL	-7.52403	-7.63743
HLA-A24:02	5HGA	4768	LAMVIEGAFDVELL	-5.82433	-6.85963
HLA-B27:05	6PYJ	4768	LAMVIEGAFDVELL	-3.28285	-4.31815
HLA-B44:05	3DX8	4768	LAMVIEGAFDVELL	-5.91172	-6.94702
HLA-B44:05	3DX8	4768	LAMVIEGAFDVELL	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of DPY19L4-ALG5

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
DPY19L4-ALG5	chr8	95782799	chr13	37526736	10	19	IEGAFDVEL	TATAGAAGGGGCATTTGATGTAGAACT
DPY19L4-ALG5	chr8	95782799	chr13	37526736	10	21	IEGAFDVELLY	TATAGAAGGGGCATTTGATGTAGAACTACTGTA
DPY19L4-ALG5	chr8	95782799	chr13	37526736	11	21	EGAFDVELLY	AGAAGGGGCATTTGATGTAGAACTACTGTA
DPY19L4-ALG5	chr8	95782799	chr13	37526736	12	21	GAFDVELLY	AGGGGCATTTGATGTAGAACTACTGTA
DPY19L4-ALG5	chr8	95782799	chr13	37526736	5	14	SLAMVIEGA	TTCTCTTGCAATGGTTATAGAAGGGGC
DPY19L4-ALG5	chr8	95782799	chr13	37526736	6	15	LAMVIEGAF	TCTTGCAATGGTTATAGAAGGGGCATT
DPY19L4-ALG5	chr8	95782799	chr13	37526736	8	17	MVIEGAFDV	AATGGTTATAGAAGGGGCATTTGATGT
DPY19L4-ALG5	chr8	95782799	chr13	37526736	8	19	MVIEGAFDVEL	AATGGTTATAGAAGGGGCATTTGATGTAGAACT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of DPY19L4-ALG5

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
CESC	DPY19L4-ALG5	chr8	95782799	ENST00000414645	chr13	37526736	ENST00000239891	TCGA-C5-A1BM

Top

Potential target of CAR-T therapy development for DPY19L4-ALG5

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

DPY19L4

chr8:95782799

chr13:37526736

ENST00000414645

161_178

484

724.0

Transmembrane

Helical

Hgene

DPY19L4

chr8:95782799

chr13:37526736

ENST00000414645

184_202

484

724.0

Transmembrane

Helical

Hgene

DPY19L4

chr8:95782799

chr13:37526736

ENST00000414645

222_240

484

724.0

Transmembrane

Helical

Hgene

DPY19L4

chr8:95782799

chr13:37526736

ENST00000414645

260_280

484

724.0

Transmembrane

Helical

Hgene

DPY19L4

chr8:95782799

chr13:37526736

ENST00000414645

292_310

484

724.0

Transmembrane

Helical

Hgene

DPY19L4

chr8:95782799

chr13:37526736

ENST00000414645

316_337

484

724.0

Transmembrane

Helical

Hgene

DPY19L4

chr8:95782799

chr13:37526736

ENST00000414645

349_370

484

724.0

Transmembrane

Helical

Hgene

DPY19L4

chr8:95782799

chr13:37526736

ENST00000414645

421_441

484

724.0

Transmembrane

Helical

Hgene

DPY19L4

chr8:95782799

chr13:37526736

ENST00000414645

466_486

484

724.0

Transmembrane

Helical

Hgene

DPY19L4

chr8:95782799

chr13:37526736

ENST00000414645

52_72

484

724.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to DPY19L4-ALG5

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to DPY19L4-ALG5

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)